<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668926/" ref="ordinalpos=2082&amp;ncbi_uid=1859616&amp;link_uid=PMC2668926" image-link="/pmc/articles/PMC2668926/figure/fig1/" class="imagepopup">Figure 1.  From: Anti-EGFR Therapy: Mechanism and Advances in  Clinical Efficacy in Breast Cancer. </a></div><br /><div class="p4l_captionBody"> The EGFR Signaling Pathway. (a) Upon EGF-ligand binding to the EGFR there is subsequent dimerization (homo- or hetero-) and tyrosine kinase residue auto-/transphosphorylation of dimer partners, which in turn initiates the actual downstream signaling pathways. (b) Ras signaling cascade in tabulated form. (c) PI3K signaling cascade in tabulated form.</div></div>